Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01088919 · ClinicalTrials.gov registry record · Phase 1

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

A Phase 1 study of Healthy and Pharmacokinetics of ASP1941, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target
1
Study location

NCT01088919: Completed Phase 1 study of Healthy and Pharmacokinetics of ASP1941, sponsored by Astellas Pharma.

NCT01088919 is a Phase 1 study of Healthy and Pharmacokinetics of ASP1941 that has completed, run by Astellas Pharma. The registered enrollment target is 64 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01088919, a Phase 1 study of Healthy and Pharmacokinetics of ASP1941, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and pioglitazone hydrochloride in multiple and single doses.

Interventions

  • DRUG ASP1941
  • DRUG pioglitazone hydrochloride

Study Locations (1)

Florida

  • - Miami

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2009-11
Est. Completion 2009-12
Phase Phase 1
Astellas Pharma

165 total trials

What the finished NCT01088919 record still lists

NCT01088919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which ASP1941 is the first listed.

NCT01088919 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT01088919 about?

NCT01088919 is a clinical study titled "A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects". The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and pioglitazone hydrochloride in multiple and single doses.

What is the current status of trial NCT01088919?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2009-11. Estimated completion is 2009-12.

What conditions does trial NCT01088919 study?

This clinical trial studies the following conditions: Healthy, Pharmacokinetics of ASP1941.

What interventions are being tested in trial NCT01088919?

The interventions under investigation include: ASP1941 (DRUG), pioglitazone hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01088919?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01088919 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01088919's enrollment target sits among peer trials

64 353rd of 1090 higher than 731 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01088919, the US trial registry maintained by the National Library of Medicine. NCT01088919 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.